此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

This Study Compares the Conventional Cutting Seton Technique and a GLUBRAN®-Coated Seton in High Perianal Fistula Treatment. The Study Aims to Determine Whether the GLUBRAN®-Coated Seton Improves Healing, Reduces Postoperative Pain and Recurrence, and Better Preserves Anal Continence.

2026年6月27日 更新者:Ahmed Monged Ibrahim Yousef Swedan、Kasr El Aini Hospital

Comparative Study Between Regular Seton and GLUBRAN® Coated Seton in the Management of High Anal Fistula (Novel Technique)

High anal fistula is a complex anorectal condition that can cause persistent pain, purulent discharge, recurrent infection, and a significant reduction in quality of life. The conventional cutting seton technique is an established treatment modality; however, it may be associated with postoperative pain, delayed healing, recurrence, and impairment of anal continence. GLUBRAN® is a synthetic surgical adhesive with antimicrobial and tissue-healing properties that may enhance the performance of the cutting seton and improve clinical outcomes.

This randomized controlled clinical trial aims to compare the efficacy and safety of a conventional cutting seton with a GLUBRAN®-coated cutting seton in adult patients with high anal fistulas. Eligible participants will be randomly allocated to one of the two treatment groups and followed for six months after surgery. The primary and secondary outcome measures will include fistula healing rate, time to complete healing, postoperative pain, anal continence, recurrence, postoperative complications, and length of hospital stay.

The findings of this study may provide evidence regarding whether coating a cutting seton with GLUBRAN® offers clinical advantages over the conventional technique, potentially leading to improved healing, reduced postoperative morbidity, and better preservation of anal continence in the management of high anal fistulas.

研究概览

地位

主动,不招人

条件

详细说明

High anal fistula is a challenging anorectal disorder characterized by an abnormal communication between the anal canal and the perianal skin that involves a significant portion of the anal sphincter complex. Patients with high anal fistulas commonly present with persistent perianal pain, recurrent abscess formation, purulent discharge, local irritation, and a substantial reduction in quality of life. These fistulas are considered complex because of their anatomical relationship with the anal sphincter muscles and the increased risk of postoperative continence impairment following surgical treatment. Consequently, the ideal management strategy should achieve complete eradication of the fistula tract while preserving sphincter function and minimizing the risk of recurrence.

The cutting seton technique has long been used as a sphincter-preserving surgical approach for the management of high anal fistulas. The procedure involves placement of a seton through the fistula tract, allowing gradual division of the sphincter muscle while promoting fibrosis and controlled healing. Although this technique has demonstrated satisfactory healing rates in numerous studies, concerns remain regarding postoperative pain, prolonged healing time, recurrence, local infection, and varying degrees of fecal incontinence. Therefore, ongoing efforts have focused on identifying modifications that may improve clinical outcomes while maintaining the effectiveness of the procedure.

GLUBRAN® is a synthetic cyanoacrylate-based surgical adhesive that has been used in multiple surgical specialties because of its adhesive, hemostatic, sealing, and bacteriostatic properties. Experimental and clinical evidence suggests that cyanoacrylate-based materials may reduce bacterial colonization, attenuate local inflammatory responses, provide mechanical support to healing tissues, and promote tissue repair. Coating a cutting seton with GLUBRAN® may therefore enhance the therapeutic effect of the procedure by reducing local infection, minimizing tissue irritation, facilitating wound healing, and potentially decreasing postoperative complications. Despite these theoretical advantages, there is currently limited clinical evidence directly comparing GLUBRAN®-coated cutting setons with conventional cutting setons in the management of high anal fistulas.

This study is designed as a prospective, randomized controlled clinical trial conducted at Cairo University Hospitals to evaluate the efficacy and safety of GLUBRAN®-coated cutting setons compared with conventional cutting setons in adult patients with high anal fistulas. Eligible participants will include patients aged 18 years or older with high trans-sphincteric, suprasphincteric, extrasphincteric, or otherwise complex anal fistulas confirmed by clinical examination and magnetic resonance imaging (MRI) fistulography. Patients with Crohn's disease, tuberculosis, malignancy-associated fistulas, radiation-induced fistulas, active perianal abscesses, or significant uncontrolled medical conditions that may interfere with wound healing will be excluded.

Following enrollment, participants will be randomly allocated in a 1:1 ratio to one of two treatment groups. Patients assigned to the control group will undergo conventional cutting seton placement using silk suture material. Patients assigned to the intervention group will undergo placement of a silk cutting seton coated with GLUBRAN® surgical adhesive before insertion through the fistula tract. All procedures will be performed according to standardized operative techniques, and all participants will receive standardized postoperative care, including analgesia, antibiotic therapy when indicated, and scheduled outpatient follow-up.

Participants will be monitored throughout the postoperative period and during a six-month follow-up. Clinical assessments will evaluate wound healing, symptom resolution, postoperative pain, continence status, recurrence, and treatment-related complications. Pain severity will be assessed using the Numerical Rating Scale (NRS), while continence will be evaluated using the validated Wexner Continence Score. Additional outcome measures will include postoperative infection, abscess formation, bleeding, length of hospital stay, need for reintervention, and overall postoperative recovery.

The primary objectives of this study are to compare complete healing rates, time to complete healing, and preservation of anal continence between the two treatment groups. Secondary objectives include comparing postoperative pain, complication rates, recurrence rates, and length of hospital stay. By systematically evaluating these outcomes, this study seeks to determine whether coating a cutting seton with GLUBRAN® provides clinically meaningful benefits over the conventional technique.

The results of this trial are expected to provide valuable evidence regarding the role of GLUBRAN® in the management of high anal fistulas. If shown to improve healing while reducing postoperative complications and preserving anal continence, GLUBRAN®-coated cutting setons may represent a safe and effective modification of the conventional cutting seton technique. The findings may help guide future surgical practice, optimize patient outcomes, and improve the quality of care provided to patients with this challenging condition.

研究类型

介入性

注册 (实际的)

36

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Giza Governorate
      • Giza、Giza Governorate、埃及、11562
        • Kasr Al Ainy Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria: - Patients diagnosed with high trans-sphincteric/Extrasphinteric/supra-sphincteric/complex Fistula confirmed clinically and MRI Fistulogram

  • Age ≥ 18 years
  • Patients fit for surgery.

Exclusion Criteria:

  • Patients with Crohn's disease, tuberculosis, malignancy, or radiation-associated fistulas (due to different healing patterns and management protocols).
  • Presence of acute perianal abscess at the time of surgery
  • Patients with uncontrolled comorbidities (e.g., diabetes mellitus, bleeding disorders, immunosuppression) that could affect healing.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Glubran-coated Seton
Using Glubran combined with Seton in the managment of high/complex perianal fistula
Using 2 ampules of no. 1 Vicryl suture as a Seton combined with Glubran 2 in the management of high/complex perianal fistula
有源比较器:Seton
Using regular Seton that is already established in the management of high/complex perianal fistula
Using 2 ampules of no. 1 Vicryl as a regular Seton

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Continence
大体时间:6 months
Assessment of continence status using a validated scoring system (e.g., Wexner Incontinence Score) to compare the impact of both techniques on sphincter function. (0 - 20) 0 being no incontinence, and 20 being no continence.
6 months
Healing Rate
大体时间:6 months
To compare the complete healing rate and time of complete healing after treatment using either Seton placement or GLUBRAN®-coated Seton over a standardized follow-up period of 6 months
6 months

次要结果测量

结果测量
措施说明
大体时间
Hospital Stay Duration
大体时间:2 days
Hospital Stay Duration
2 days
Incidence of complications such as infection, abscess formation, bleeding.
大体时间:6 months
Incidence of complications such as infection, abscess formation, bleeding.
6 months
Recurrence
大体时间:6 months
Short-term Recurrence Rate
6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Ismail A Shafik, M.D.、Kasr El Aini Hospital
  • 研究主任:Abdelrahman M. Ibrahim, M.D.、Kasr El Aini Hospital
  • 首席研究员:Ahmed Y. Ahmed, M.D.、Kasr El Aini Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年1月11日

初级完成 (估计的)

2026年7月11日

研究完成 (估计的)

2026年7月11日

研究注册日期

首次提交

2026年6月23日

首先提交符合 QC 标准的

2026年6月27日

首次发布 (实际的)

2026年6月30日

研究记录更新

最后更新发布 (实际的)

2026年6月30日

上次提交的符合 QC 标准的更新

2026年6月27日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • MS-682-2025

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared publicly due to patient confidentiality considerations, the sensitive nature of clinical surgical data, and institutional data protection policies. Only aggregated results will be reported.

研究数据/文件

  1. 个人参与者数据集
    信息评论:https://docs.google.com/spreadsheets/d/1eZjb7Xju7cntbPTareModXlZGJnS0d2k/edit?usp=drive_link&ouid=114042876965075600816&rtpof=true&sd=true
  2. 研究协议
    信息评论:https://docs.google.com/document/d/195jb55EeL0QlIpf659zT3y2dg3x_eRGt/edit?usp=drive_link&ouid=114042876965075600816&rtpof=true&sd=true

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅